Shares of Biocon Ltd rose 1.25% to touch the day’s high of Rs 396.40 on 25th February, after the company announced on Tuesday, 24th February, that it had received approval from the US Food and Drug Administration (USFDA) for its complex formulation, Liraglutide Injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda).
Liraglutide is a drug-device combination used for chronic weight management. It is prescribed along with a reduced-calorie diet and increased physical activity to help individuals manage obesity.
GLP-1 receptor agonists are among the fastest-growing therapy segments globally. The rise in obesity and metabolic disorders, strong clinical outcomes, and increasing doctor adoption are driving their demand.
According to IQVIA MAT December 2025 data, the total addressable GLP-1 market for weight loss in the United States stood at $127 million.
Siddharth Mittal, CEO and Managing Director of Biocon Ltd, said the US approval of gSaxenda is a major milestone for the company. He noted that it reflects Biocon’s scientific capabilities and integrated manufacturing strength, and supports its global expansion strategy. He added that GLP-1 therapies are an important growth driver, with the US being a key market. The company aims to commercialise Liraglutide (gSaxenda) as soon as possible to offer an affordable treatment option to US patients.
What is GLP-1?
Glucagon-like peptide-1 (GLP-1) is a natural gut hormone. GLP-1 medicines help lower blood sugar and promote weight loss by increasing insulin secretion, reducing glucagon secretion, slowing gastric emptying, and reducing appetite.
What is Liraglutide?
Liraglutide is a synthetic GLP-1 receptor agonist administered once daily by injection. It was approved in the European Union in 2009 and in the United States in 2010. In 2014, the US FDA approved it for weight management in obese or overweight adults with related conditions.
In 2019, it was approved in the US for children aged 10 years and above with type 2 diabetes, becoming the first non-insulin treatment for children with the condition since metformin was approved in 2000.
At 12:26 PM, shares of Biocon Ltd were trading 1.28% higher at Rs 395.75 on the NSE.
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!
